



**PEC** PHARMA  
EDUCATION  
CENTER

*International experts will be discussing hot topics and case studies, including interactive Q&A and round tables with the involvement of all the participants. Speakers and delegates will share their experiences on emerging markets, strategies and new trends in Regulatory Affairs.*

# EUROPEAN REGULATORY AFFAIRS FORUM 2021

MAY 12 - 13 | ONLINE

**#EURA2021**



# TOPICS

## **THE REGULATORY FRAMEWORK OF INNOVATIVE THERAPIES**

This session will introduce the regulatory landscape and will discuss hands on experiences of registration process related to Novel Therapies - ATMPs. Due to their high complexity and multiple potential, ATMPs are subject to continuously evolving regulatory requirements. Regulatory professionals will share their experience on the registration synergies needed for accelerating the availability of these therapies on the market.

**Case studies and keynote presentations followed by a final panel discussion with the involvement of participants.**

## **THE REGULATORY LANDSCAPE AFTER BREXIT**

Brexit affected significantly many activities in the pharmaceutical and lifescience industry, such as marketing authorisations and drug approval procedures, rules on Good Manufacturing Practice (GMP), pharmacovigilance and clinical trials.

A MHRA expert has been invited to present the main impacts of Brexit implementation on regulatory and marketing, at four months from come into force.

**Q&A session will follow.**

## **DRUG-DEVICE COMBINATION: An evolving global Regulatory scenario**

The manufacturers/MAH are required to fully understand and apply the specific requirements in each country in order to ensure a timely and accurate market access of new combination products, a market that is constantly growing over years.

Regulatory Affairs experts from companies will share their experience during keynote presentations and a panel discussion with the involvement of participants.

## **EXTRA EU AND EMERGING MARKETS: REGULATORY ASPECTS AND CHALLENGES**

Emerging markets have complex healthcare systems under rapid evolution, requiring a constant effort to ensure an effective market access.

Experts will share their regulatory experience, discussing the opportunities and challenges posed by these countries.

**Keynote presentations followed by a final panel discussion with participants**

## **THE PHARMA DIGITALIZATION**

The digital transformation is affecting the whole product lifecycle, from R&D to product supply and patient care, bringing patients and their quality of life to the centre of the pharma business.

In this session Regulatory Experts from leading industries will share their point of view about digital regulatory models and digitalization in therapies.

**Keynote presentations followed by a final panel discussion with participants**

# TOPICS workshop

## THE ICH Q12 GUIDELINE: CHALLENGES AND OPPORTUNITIES

The key points of the guideline will be presented and discussed, together with the potential benefits for the MAH of using the tools and enablers described in ICH Q12 guideline, with reference to the current EU legal framework.

**The presentation will be followed by a final panel discussion with the involvement of participants.**

## NITROSAMINES ASSESSMENT

Regulatory experts will share their experience about the implementation of the assessment of Nitrosamines impurities in the finished product dossier and the related regulatory impacts with the different authorities.

**The presentation will be followed by a final panel discussion with the involvement of participants.**

## PRICING AND REIMBURSEMENT OF MEDICINAL PRODUCTS IN ITALY

The new AIFA guideline on prices and reimbursement will be discussed, with a focus on the new requirements compared with the last version.

**The presentation will be followed by a final panel discussion with the involvement of participants.**

## ELECTRONIC COMMON TECHNICAL DOCUMENT eCTD

The eCTD is now an established digital format that pharmaceutical companies adopt for the registration of drugs, as recommended by the International Conference on Harmonisation (ICH). The speakers will share their experiences illustrating the advantages and challenges they have faced in the management of this document.

**The presentation will be followed by a final panel discussion with the involvement of participants.**

## Sponsors



## Media Partner



# PROGRAM

**MAY 12, 2021**

**09.00 Introduction**

*Chairperson: **Raffaella Pandini** - Regulatory Affairs  
Operational Manager - Pharma D&S*

*Co-chairperson: **Ilaria Brocchi** - RA Senior Project  
Manager - Pharma D&S*

## **SESSION I - THE REGULATORY FRAMEWORK OF INNOVATIVE THERAPIES**

**09.15 New therapeutic scenarios in the evolution  
of pharmaceuticals**

***Raffaele Cerbini** - Executive Medical Director*

**09.35 Early Access Regulatory Pathways (EMA FDA)  
for new Therapies**

***Paolo Dametto** - Sr. Manager - International Regulatory  
Science - Moderna*

**10.00 Rolling review & emergency procedures for COVID  
19 vaccines**

***Federica Grotti** - Head of Regulatory Affairs - Pfizer*

**10.25 Panel discussion**

*Moderator: **Raffaele Cerbini***

*Participants:*

- **Patrizia Ciavatta** - Global Regulatory Affairs  
Executive Director - Angelini
- **Paolo Dametto** - Moderna
- **Federica Grotti** - Pfizer

**11.00 Coffee break**

## **SESSION II - THE REGULATORY LANDSCAPE AFTER BREXIT**

**11.20 A Globally Attractive UK ?**

***Phil Brown** - Director, Regulatory & Compliance -  
Association of British HealthTech Industries*

**11.50 Q&A time**

## **SESSION III - EXTRA EU AND EMERGING MARKETS: REGULATORY ASPECTS AND CHALLENGES**

**12.05 Regulatory Strategies for Inclusion of China into the  
Global Development of Innovative Drugs**

***Stefano Accorsi** - MSc EMBA - Head of Regulatory  
Affairs "China and International", Global Regulatory  
Affairs - Chiesi Farmaceutici S.p.A.*



# PROGRAM

12.30 **Eurasian Economic Union: an overview and experience from the first wave of harmonizations**  
*Alessandra Leone* - Global CMC Senior Manager - PTx - Pfizer

13.00 **Lunch**

14.00 **Panel discussion**

- *Stefano Accorsi* - Chiesi Farmaceutici S.p.A
- *Marcello Colao* - Sr Director, Global Quality Head China Vaccines - GSK
- *Alessandra Leone* - Pfizer

## SESSION IV - THE PHARMA DIGITALIZATION

14.30 **Business impacts caused by the switch from eCTD 3.2 to the next major version eCTD 4.0**  
*Frank Dickert* - Senior Business Consultant - EXTEDO

14.50 **Q&A time**

15.00 **Digital health transformation and innovative technologies in healthcare**  
*Roberto Ascione* - CEO - Healthware Group

15.25 **The evolving global regulatory landscape for digital health software**  
*Priya Tiwari* - Associate Director Global Regulatory Affairs - Digital Health, Combination Products and Medical Devices - Biogen

15.50 **Panel discussion**

## SESSION V - DRUG-DEVICE COMBINATION: AN EVOLVING GLOBAL REGULATORY SCENARIO

16.10 **Comparison MDR-FDA legislation in the registration of combined products**  
*Priya Tiwari* - Associate Director Global Regulatory Affairs - Digital Health, Combination Products and Medical Devices - Biogen

16.35 **Q&A time**

16.50 **Final remarks & Closure**  
*Raffaella Pandini* - Regulatory Affairs Operational Manager - Pharma D&S

17.00 **End of the Forum**





## WORKSHOP

**MAY 13, 2021**

**09.00 Introduction**

*Chairperson: **Raffaella Pandini** - Regulatory Affairs  
Operational Manager - Pharma D&S*

*Co-chairperson: **Stefano Nepi** - Team Leader Project  
Manager - Pharma D&S*

### SESSION VI - THE ICH Q12 GUIDELINE: CHALLENGES AND OPPORTUNITIES

**09.15 Lifecycle Management of Pharmaceutical Products  
Global Harmonization of Post-Approval  
Changes (ICH Q12)**

***Jean Louis Robert** - EU topic leader for Life Cycle  
Management ICH Q12 - former chair of CHMP-QWP*

**09.45 Implementation of ICH Q12 - an Industry Perspective**

***Mihai Bilanin** - Director, Global Regulatory CMC -  
GSK Biopharmaceuticals*

**10.15 Panel discussion**

### SESSION VII - NITROSAMINES ASSESSMENT

**10.30 NITROSAMINES: RA points of situation and  
experience with European HAs**

***Raffaella Pandini** - Regulatory Affairs Operational  
Manager - Pharma D&S*

**10.55 Q&A time**

**11.10 Coffee break**

### SESSION VIII - PRICING AND REIMBURSEMENT OF PHARMACEUTICALS IN ITALY

**11.30 The new AIFA Pricing & Reimbursement guideline:  
overview and differences with the previous dossier**

***Alessandra Perini** - Avv., LL.M. (UCL) - In-house  
Counsuel - Pharmaceutical Legal Expert*

**12.00 Q&A time**

### SESSION IX - ELECTRONIC COMMON TECHNICAL DOCUMENT - eCTD

**12.15 The electronic Common Technical Dossier (eCTD):  
experience with ASMF**

***Lisa Milazzo** - Regulatory Affairs Consultant - Pharma D&S*

**12.40 The electronic Common Technical Dossier (eCTD) and  
important regional differences**

***Hans Rensland** - Managing Director - Racon Regulatory  
Affairs Consulting GmbH*

**13.05 Panel discussion**

**13.20 Closure of the Forum**

# SPEAKERS




**Stefano Accorsi**

MSc EMBA - Head of Regulatory Affairs "China and International", Global Regulatory Affairs - Chiesi Farmaceutici S.p.A.



**Raffaele Cerbini**

Executive Medical Director



**Roberto Ascione**

CEO - Healthware Group



**Patrizia Ciavatta**

Global Regulatory Affairs  
Executive Director - Angelini



**Mihai Bilanin**

Director, Global Regulatory CMC -  
GSK Biopharmaceuticals



**Marcello Colao**

Sr Director, Global Quality Head  
China Vaccines - GSK



**Ilaria Brocchi**

RA Senior Project Manager -  
Pharma D&S



**Paolo Dametto**

Sr. Manager - International  
Regulatory Science - Moderna



**Phil Brown**

Director, Regulatory &  
Compliance -  
Association of British  
HealthTech Industries



**Frank Dickert**

Senior Business Consultant -  
EXTEDO

# SPEAKERS



**Federica Grotti**

Head of Regulatory Affairs -  
Pfizer



**Alessandra Leone**

Global CMC Senior Manager -  
PTx - Pfizer



**Lisa Milazzo**

Regulatory Affairs Consultant -  
Pharma D&S



**Stefano Nepi**

Team Leader Project Manager -  
Pharma D&S



**Raffaella Pandini**

Regulatory Affairs Operational  
Manager - Pharma D&S



**Alessandra Perini**

Avv., LL.M. (UCL), In-house  
Counsel - Pharmaceutical  
Legal Expert



**Hans Rensland**

Managing Director -  
Racon Regulatory Affairs  
Consulting GmbH



**Jean Louis Robert**

EU topic leader for Life Cycle  
Management ICH Q12 -  
former chair of CHMP - QWP



**Priya Tiwari**

Associate Director, Regulatory  
Affairs Digital Health, Medical  
Devices & Combination  
Products - Biogen





## ENTRY FEE

600 €

500 € until March 15

550 € until April 12

Discounts are not  
cumulative

VAT not included

### TERMS OF PAYMENT

Advance payment is required with respect to the event date by bank transfer to BANCO BPM Spa - Florence (Italy), IBAN: IT90U0503402815000000001400, Bic/SWIFT: BAPPIT21G74 made payable to Pharma Education Center S.r.l., Via dei Pratoni 16, 50018 Scandicci (FI), VAT number 02173670486, specifying event title along with name and surname of the participant enrolling. Attendance to the event will be allowed upon payment received. Invoice of payment will be issued after the second half of the month after the course.

**For further information and/or further assistance please contact (+39) 055 7224179 or email: [amministrazione@pharmaeducationcenter.it](mailto:amministrazione@pharmaeducationcenter.it)**

### COURSE/EVENT CANCELLATION

If the minimum number of participants is not reached, Pharma Education Center reserves the right to cancel or schedule the event for another date. Formal communication will be given within 5 days before the event date. In this case Pharma Education Center will refund the registration fee in full and without additional charges. Alternatively, the participant can request a spendable coupon for participating in another PEC event scheduled in the current year.

### CANCELLATION TERMS

In order to cancel enrolment to a event, please email [info@pharmaeducationcenter.it](mailto:info@pharmaeducationcenter.it) within 2 weeks before the starting date of the event. Once this term will be expired, the entire fee will be charged.

### PARTICIPANT REPLACEMENT

It is possible to replace a participant attendance without additional cost, simply by contacting [info@pharmaeducationcenter.it](mailto:info@pharmaeducationcenter.it). It is asked to notify the participant replacement request within 5 days before the starting date of the course/event, specifying the full name and surname of the enrolled participant as well as the full name and surname of the substitute.

### HOW TO REGISTER

Please, fill the form on the web site <https://www.pharmaeducationcenter.it/>

## 📍 ONLINE

Tel (+39) 055 7224179

(+39) 055 7224076

Fax (+39) 055 7227014

[info@pharmaeducationcenter.it](mailto:info@pharmaeducationcenter.it)

**PEC** PHARMA  
EDUCATION  
CENTER

To stay  
updated on  
our courses  
Follow us on

